Emerging Concepts in Managing Malignancy in Kidney Transplant Patients

Brittany Schreiber; Maen Abdelrahim; Ala Abudayyeh; Naoka Murakami

doi:10.1016/j.semnephrol.2022.01.003

Emerging Concepts in Managing Malignancy in Kidney Transplant Patients

Brittany Schreiber, Maen Abdelrahim, Ala Abudayyeh, Naoka Murakami

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Cancer remains a significant cause of morbidity and mortality in kidney transplant recipients, due to long-term immunosuppression. Salient issues to consider in decreasing the burden of malignancy among kidney transplant recipients include pretransplant recipient evaluation, post-transplant screening and monitoring, and optimal treatment strategies for the kidney transplant recipients with cancer. In this review, we address cancer incidence and outcomes, approaches to cancer screening and monitoring pretransplant and post-transplant, as well as treatment strategies, immunosuppressive management, and multidisciplinary approaches in the kidney transplant recipients with cancer.

Original language	English (US)
Pages (from-to)	63-75
Number of pages	13
Journal	Seminars in nephrology
Volume	42
Issue number	1
DOIs	https://doi.org/10.1016/j.semnephrol.2022.01.003
State	Published - Jan 2022

Keywords

Kidney transplant
PTLD
cancer
immunotherapy
oncology
wait time
Kidney Transplantation/adverse effects
Immunosuppressive Agents/adverse effects
Humans
Immunosuppression Therapy/adverse effects
Neoplasms/epidemiology

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/j.semnephrol.2022.01.003

Cite this

@article{c3b3194519224a6fab286c7f84408793,

title = "Emerging Concepts in Managing Malignancy in Kidney Transplant Patients",

abstract = "Cancer remains a significant cause of morbidity and mortality in kidney transplant recipients, due to long-term immunosuppression. Salient issues to consider in decreasing the burden of malignancy among kidney transplant recipients include pretransplant recipient evaluation, post-transplant screening and monitoring, and optimal treatment strategies for the kidney transplant recipients with cancer. In this review, we address cancer incidence and outcomes, approaches to cancer screening and monitoring pretransplant and post-transplant, as well as treatment strategies, immunosuppressive management, and multidisciplinary approaches in the kidney transplant recipients with cancer.",

keywords = "Kidney transplant, PTLD, cancer, immunotherapy, oncology, wait time, Kidney Transplantation/adverse effects, Immunosuppressive Agents/adverse effects, Humans, Immunosuppression Therapy/adverse effects, Neoplasms/epidemiology",

author = "Brittany Schreiber and Maen Abdelrahim and Ala Abudayyeh and Naoka Murakami",

note = "Funding Information: Financial disclosure and conflict of interest statements: none. Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = jan,

doi = "10.1016/j.semnephrol.2022.01.003",

language = "English (US)",

volume = "42",

pages = "63--75",

journal = "Seminars in nephrology",

issn = "0270-9295",

publisher = "W.B. Saunders Ltd",

number = "1",

}

TY - JOUR

T1 - Emerging Concepts in Managing Malignancy in Kidney Transplant Patients

AU - Schreiber, Brittany

AU - Abdelrahim, Maen

AU - Abudayyeh, Ala

AU - Murakami, Naoka

PY - 2022/1

Y1 - 2022/1

N2 - Cancer remains a significant cause of morbidity and mortality in kidney transplant recipients, due to long-term immunosuppression. Salient issues to consider in decreasing the burden of malignancy among kidney transplant recipients include pretransplant recipient evaluation, post-transplant screening and monitoring, and optimal treatment strategies for the kidney transplant recipients with cancer. In this review, we address cancer incidence and outcomes, approaches to cancer screening and monitoring pretransplant and post-transplant, as well as treatment strategies, immunosuppressive management, and multidisciplinary approaches in the kidney transplant recipients with cancer.

AB - Cancer remains a significant cause of morbidity and mortality in kidney transplant recipients, due to long-term immunosuppression. Salient issues to consider in decreasing the burden of malignancy among kidney transplant recipients include pretransplant recipient evaluation, post-transplant screening and monitoring, and optimal treatment strategies for the kidney transplant recipients with cancer. In this review, we address cancer incidence and outcomes, approaches to cancer screening and monitoring pretransplant and post-transplant, as well as treatment strategies, immunosuppressive management, and multidisciplinary approaches in the kidney transplant recipients with cancer.

KW - Kidney transplant

KW - PTLD

KW - cancer

KW - immunotherapy

KW - oncology

KW - wait time

KW - Kidney Transplantation/adverse effects

KW - Immunosuppressive Agents/adverse effects

KW - Humans

KW - Immunosuppression Therapy/adverse effects

KW - Neoplasms/epidemiology

UR - http://www.scopus.com/inward/record.url?scp=85124400262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124400262&partnerID=8YFLogxK

U2 - 10.1016/j.semnephrol.2022.01.003

DO - 10.1016/j.semnephrol.2022.01.003

M3 - Review article

C2 - 35618396

AN - SCOPUS:85124400262

SN - 0270-9295

VL - 42

SP - 63

EP - 75

JO - Seminars in nephrology

JF - Seminars in nephrology

IS - 1

ER -

Emerging Concepts in Managing Malignancy in Kidney Transplant Patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this